157 related articles for article (PubMed ID: 12707351)
1. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection.
Verthelyi D; Gursel M; Kenney RT; Lifson JD; Liu S; Mican J; Klinman DM
J Immunol; 2003 May; 170(9):4717-23. PubMed ID: 12707351
[TBL] [Abstract][Full Text] [Related]
2. CpG oligodeoxynucleotides as vaccine adjuvants in primates.
Verthelyi D; Kenney RT; Seder RA; Gam AA; Friedag B; Klinman DM
J Immunol; 2002 Feb; 168(4):1659-63. PubMed ID: 11823494
[TBL] [Abstract][Full Text] [Related]
3. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs.
Flynn B; Wang V; Sacks DL; Seder RA; Verthelyi D
Infect Immun; 2005 Aug; 73(8):4948-54. PubMed ID: 16041009
[TBL] [Abstract][Full Text] [Related]
4. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.
Becker Y
Virus Genes; 2005 Mar; 30(2):251-66. PubMed ID: 15744581
[TBL] [Abstract][Full Text] [Related]
5. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.
Mendez S; Tabbara K; Belkaid Y; Bertholet S; Verthelyi D; Klinman D; Seder RA; Sacks DL
Infect Immun; 2003 Sep; 71(9):5121-9. PubMed ID: 12933855
[TBL] [Abstract][Full Text] [Related]
6. CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques.
Verthelyi D; Wang VW; Lifson JD; Klinman DM
AIDS; 2004 Apr; 18(7):1003-8. PubMed ID: 15096802
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides.
Wu W; Weigand L; Belkaid Y; Mendez S
Eur J Immunol; 2006 Dec; 36(12):3238-47. PubMed ID: 17109471
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.
Ramírez-Pineda JR; Fröhlich A; Berberich C; Moll H
J Immunol; 2004 May; 172(10):6281-9. PubMed ID: 15128817
[TBL] [Abstract][Full Text] [Related]
10. CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells.
Teleshova N; Kenney J; Jones J; Marshall J; Van Nest G; Dufour J; Bohm R; Lifson JD; Gettie A; Pope M
J Immunol; 2004 Aug; 173(3):1647-57. PubMed ID: 15265893
[TBL] [Abstract][Full Text] [Related]
11. CpG-C ISS-ODN activation of blood-derived B cells from healthy and chronic immunodeficiency virus-infected macaques.
Teleshova N; Kenney J; Williams V; Van Nest G; Marshall J; Lifson JD; Sivin I; Dufour J; Bohm R; Gettie A; Pope M
J Leukoc Biol; 2006 Feb; 79(2):257-67. PubMed ID: 16443827
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.
Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899
[TBL] [Abstract][Full Text] [Related]
13. Use of CpG oligodeoxynucleotides as immunoprotective agents.
Klinman DM
Expert Opin Biol Ther; 2004 Jun; 4(6):937-46. PubMed ID: 15174975
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma.
Ursu R; Carpentier AF
Adv Exp Med Biol; 2012; 746():95-108. PubMed ID: 22639162
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.
Rhee EG; Mendez S; Shah JA; Wu CY; Kirman JR; Turon TN; Davey DF; Davis H; Klinman DM; Coler RN; Sacks DL; Seder RA
J Exp Med; 2002 Jun; 195(12):1565-73. PubMed ID: 12070284
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
[TBL] [Abstract][Full Text] [Related]
17. Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides.
Kamstrup S; Verthelyi D; Klinman DM
Vet Microbiol; 2001 Feb; 78(4):353-62. PubMed ID: 11182501
[TBL] [Abstract][Full Text] [Related]
18. Functional analyses of natural killer cells in macaques infected with neurovirulent simian immunodeficiency virus.
Shieh TM; Carter DL; Blosser RL; Mankowski JL; Zink MC; Clements JE
J Neurovirol; 2001 Feb; 7(1):11-24. PubMed ID: 11519478
[TBL] [Abstract][Full Text] [Related]
19. Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates.
Puig M; Grajkowski A; Boczkowska M; Ausín C; Beaucage SL; Verthelyi D
Nucleic Acids Res; 2006; 34(22):6488-95. PubMed ID: 17130156
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.
Ramírez L; Santos DM; Souza AP; Coelho EA; Barral A; Alonso C; Escutia MR; Bonay P; de Oliveira CI; Soto M
Vaccine; 2013 Feb; 31(9):1312-9. PubMed ID: 23313653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
